Humana Specialty Pharmacy Expands Access to New Cancer Treatment Options
Patients can now receive the following drugs, delivered to their front doors in a fast and meaningful way, while
- TAGRISSO® (osimertinib), a drug that helps certain patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) manage their disease.
- LENVIMA® (lenvatinib), a drug that helps patients with different forms of cancer, including certain types of thyroid, liver and kidney cancers.
Patients who receive TAGRISSO and LENVIMA from
“We are honored to be able to dispense these therapies and offer differentiated service and experience to patients through our
More information about
About Humana
To accomplish that, we support physicians and other health care professionals as they work to deliver the right care in the right place for their patients, our members. Our range of clinical capabilities, resources and tools – such as in-home care, behavioral health, pharmacy services, data analytics and wellness solutions – combine to produce a simplified experience that makes health care easier to navigate and more effective.
More information regarding Humana is available to investors via the Investor Relations page of the company’s web site at www.humana.com, including copies of:
- Annual reports to stockholders
-
Securities and Exchange Commission filings - Most recent investor conference presentations
- Quarterly earnings news releases and conference calls
- Calendar of events
- Corporate Governance information
View source version on businesswire.com: https://www.businesswire.com/news/home/20220208005470/en/
832-330-4702
ldimond@humana.com
Source: